# US 2019/0169311 A1 · Human Antibodies Against Tissue Factor and Methods of Use Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0169311 A1
- Document ID: US20190169311A1
- Status: Published application
- Kind: A1
- Application number: 15/998,816
- Filed: 2018-08-16
- Published: 2019-06-06
- Earliest claimed: 2008-12-09
- Assignees: Genmab A/S
- Applicants: Genmab A/S
- Inventors: Sandra Verploegen; David P.E. Satijn; Rene M.A. Hoet; Paul Parren; Jan Van De Winkel; Vibeke Miller Breinholt; Eva Ehrnrooth; Ole Baadsgaard; Tom Vink; Willem Karel Bleeker; Mischa Houtkamp; Maroeska Oudshoorn; Rob N. De Jong
- Web page: https://patentgrep.com/patent/US20190169311A1

## CPC

- C07K 16/36: against blood coagulation factors
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 13/08: of the prostate
- A61P 13/10: of the bladder
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 15/08: for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A61P 15/14: for lactation disorders, e.g. galactorrhoea
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 2039/505: {comprising antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/31: multispecific
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Isolated human monoclonal antibodies which bind to human TF and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, and therapeutic and diagnostic methods for using the antibodies.

## Claims

### Claim at position 1

1-88. (canceled)

### Claim 89

A human antibody which binds human Tissue Factor wherein said antibody:
a) does not compete for Tissue Factor binding with an antibody comprising a VH region comprising the sequence of SEQ ID NO:9 and a VL region comprising the sequence of SEQ ID NO:65, and
b) competes for Tissue Factor binding with an antibody comprising a VH region comprising the sequence of SEQ ID NO:37 and a VL region comprising the sequence of SEQ ID NO:93.

### Claim 90 (depends on 89)

The antibody of claim 89, wherein the antibody binds to the extracellular domain of Tissue Factor with an apparent affinity (EC50) of 0.50 nM or less, when determined as described in the assay in Example 13.

### Claim 91 (depends on 89)

The antibody of claim 89, wherein the antibody binds to mammalian cells expressing Tissue Factor, such as A431 cells transfected with a construct encoding Tissue Factor, with an apparent affinity (EC50) of 8 nM or less, when determined as described in the assay in Example 14.

### Claim 92 (depends on 89)

The antibody of claim 89, wherein the antibody is capable of inducing antibody-dependent cellular cytotoxicity in A431 cells, preferably with an EC50 value of 2 nM or less, when determined as described in the assay in Example 20.

### Claim 93

(canceled)

### Claim 94 (depends on 89)

The antibody of claim 89, wherein the antibody inhibits tissue factor induced blood coagulation, with a median inhibition concentration of less than 10 nM, when determined as described in the assay in Example 19.

### Claim 95 (depends on 89)

The antibody of claim 89, wherein the antibody inhibits FVIIa-induced IL-8 release by MDA-MB-231 cells, with a maximum inhibition value of inhibition of more than 40%, when determined as described in the assay in Example 17.

### Claim 96 (depends on 89)

The antibody of claim 89, wherein the antibody inhibits conversion of FX into FXa by the TF/FVIIa complex, in the range of 1-30%, when determined as described in the assay in Example 18.

### Claim 97 (depends on 89)

The antibody of claim 89, wherein the antibody is capable of inducing C3c and C4c deposition, and wherein the antibody is capable of inducing C3c and C4c deposition as determined in Example 21.

### Claim 98 (depends on 89)

The antibody of claim 89, wherein the antibody binds to human tissue factor and not murine tissue factor and shows reduced binding as compared to binding to human TF to the shuffle construct 85-122 mm, containing the human sequence for TF except for amino acid 85-122, which has been replaced with mouse sequence, as described in Example 27.

### Claim 99

(canceled)

### Claim 100 (depends on 89)

The antibody of claim 89, wherein the antibody comprises:
a) a VH region comprising the CDR1, 2, and 3 sequences of SEQ ID NOs:30, 31, and 32, and a VL region comprising the CDR1, 2, and 3 sequences of SEQ ID NOs:86, 87, and 88,
b) a VH region comprising the CDR1, 2, and 3 sequences of SEQ ID NOs:34, 35, and 36, and a VL region comprising the CDR1, 2, and 3 sequences of SEQ ID NOs:90, 91, and 92,
c) a VH region comprising the CDR1, 2, and 3 sequences of SEQ ID NOs:38, 39, and 40, and a VL region comprising the CDR1, 2, and 3 sequences of SEQ ID NOs:94, 95, and 96,
d) a VH region comprising the CDR1, 2, and 3 sequences of SEQ ID NOs:54, 55, and 56, and a VL region comprising the CDR1, 2, and 3 sequences of SEQ ID NOs:110, 111, and 112, or
e) a variant of any of said antibodies, wherein said variant preferably has at most 1, 2, or 3 amino-acid modifications, more preferably amino-acid substitutions, such as conservative amino-acid substitutions in said sequences.

### Claim at position 14

101-102. (canceled)

### Claim 103 (depends on 89)

The antibody of claim 89 comprising:
a) a VH region comprising the sequence of SEQ ID NO:29 and a VL region comprising the sequence of SEQ ID NO:85,
b) a VH region comprising the sequence of SEQ ID NO:33 and a VL region comprising the sequence of SEQ ID NO:89,
c) a VH region comprising the sequence of SEQ ID NO:37 and a VL region comprising the sequence of SEQ ID NO:93,
d) a VH region comprising the sequence of SEQ ID NO:53 and a VL region comprising the sequence of SEQ ID NO:109, or
e) a variant of any of said antibodies, wherein said variant preferably has at most 1, 2, or 3 amino-acid.

### Claim 104 (depends on 89)

The antibody of claim 89, wherein the antibody has an affinity to tissue factor which is less than 5 nM when determined by the method described in Example 22 herein.

### Claim 105 (depends on 89)

The antibody of claim 89, wherein the antibody is effective in inhibiting growth of established BX-PC3 tumors when determined by the method described in Example 26 herein.

### Claim 106 (depends on 89)

The antibody of claim 89, wherein the antibody further has one or more of the following properties: inhibition of proliferation, inhibition of tumor angiogenesis, induction of apoptosis of tumor cells, binding to alternatively spliced Tissue Factor.

### Claim 107

(canceled)

### Claim 108 (depends on 89)

The antibody of claim 89, wherein the antibody is a full-length antibody.

### Claim 109 (depends on 89)

The antibody of claim 89, wherein the antibody is conjugated to another moiety.

### Claim 110 (depends on 89)

The antibody of claim 89, wherein the antibody is an effector-function-deficient antibody.

### Claim 111 (depends on 110)

The antibody of claim 110, wherein the effector-function-deficient anti-Tissue-Factor antibody is a stabilized human IgG4 antibody.

### Claim 112 (depends on 89)

The antibody of claim 89, wherein the antibody is a monovalent antibody.

### Claim 113 (depends on 112)

The antibody of claim 112, wherein said monovalent antibody is constructed by a method comprising:
i) providing a nucleic acid construct encoding the light chain of said monovalent antibody, said construct comprising a nucleotide sequence encoding the VL region of a selected antigen specific antibody and a nucleotide sequence encoding the constant CL region of an Ig, wherein said nucleotide sequence encoding the VL region of a selected antigen specific antibody and said nucleotide sequence encoding the CL region of an Ig are operably linked together, and wherein, in case of an IgG1 subtype, the nucleotide sequence encoding the CL region has been modified such that the CL region does not contain any amino acids capable of forming disulfide bonds or covalent bonds with other peptides comprising an identical amino acid sequence of the CL region in the presence of polyclonal human IgG or when administered to an animal or human being;
ii) providing a nucleic acid construct encoding the heavy chain of said monovalent antibody, said construct comprising a nucleotide sequence encoding the VH region of a selected antigen specific antibody and a nucleotide sequence encoding a constant CH region of a human Ig, wherein the nucleotide sequence encoding the CH region has been modified such that the region corresponding to the hinge region and, as required by the Ig subtype, other regions of the CH region, such as the CH3 region, does not comprise any amino acid residues which participate in the formation of disulphide bonds or covalent or stable non-covalent inter-heavy chain bonds with other peptides comprising an identical amino acid sequence of the CH region of the human Ig in the presence of polyclonal human IgG or when administered to an animal human being, wherein said nucleotide sequence encoding the VH region of a selected antigen specific antibody and said nucleotide sequence encoding the CH region of said Ig are operably linked together;
iii) providing a cell expression system for producing said monovalent antibody; and
iv) producing said monovalent antibody by co-expressing the nucleic acid constructs of (i) and (ii) in cells of the cell expression system of (iii).

### Claim 114 (depends on 112)

The antibody of claim 112, wherein the monovalent antibody comprises:
(i) a variable region of an antibody which binds human TF or an antigen binding part of the said region, and
(ii) a CH region of an immunoglobulin or a fragment thereof comprising the CH2 and CH3 regions, wherein the CH region or fragment thereof has been modified such that the region corresponding to the hinge region and, if the immunoglobulin is not an IgG4 subtype, other regions of the CH region do not comprise any amino acid residues, which are capable of forming disulfide bonds with an identical CH region or other covalent or stable non-covalent inter-heavy chain bonds with an identical CH region in the presence of polyclonal human IgG.

### Claim 115 (depends on 112)

The antibody of claim 112, wherein the heavy chain has been modified such that the entire hinge has been deleted.

### Claim 116 (depends on 89)

A bispecific molecule comprising an antibody of claim 89 and a second binding specificity.

### Claim 117

(canceled)

### Claim 118

An expression vector comprising a nucleotide sequence encoding one or more of the amino acid sequences selected from the group consisting of SEQ ID NOs:29-40 and SEQ ID NOs: 53-56.

### Claim 119

(canceled)

### Claim 120 (depends on 89)

A recombinant eukaryotic or prokaryotic host cell which produces the antibody of claim 89.

### Claim 121 (depends on 89)

A pharmaceutical composition comprising an antibody of claim 89, and a pharmaceutically acceptable carrier.

### Claim 122 (depends on 89)

A method of treating cancer comprising administering to a subject in need thereof an effective amount of claim 89.

### Claim 123 (depends on 122)

The method of claim 122, wherein the cancer is selected from the group consisting of: tumors of the central nervous system, head and neck cancer, lung cancer, breast cancer, esophageal cancer, stomach cancer, liver and biliary cancer, pancreatic cancer, colorectal cancer, bladder cancer, kidney cancer, prostate cancer, endometrial cancer, ovarian cancer, malignant melanoma, sarcoma, tumors of unknown primary origin, bone marrow cancer, acute lymphoblastic leukemia, chronic lymphoblastic leukemia and non-Hodgkin lymphoma, skin cancer, glioma, cancer of the brain, uterus, and rectum.

### Claim at position 36

124-130. (canceled)

### Claim 131 (depends on 89)

A method for inhibiting growth and/or proliferation of a tumor cell expressing Tissue Factor, comprising administration, to an individual in need thereof, of the antibody of claim 89.

### Claim 132 (depends on 89)

A method for producing the antibody of claim 89, said method comprising the steps of:
a) culturing a host cell which produces the antibody, and
b) purifying the antibody from the culture media.

### Claim 133 (depends on 89)

A diagnostic composition comprising the antibody of claim 89.

### Claim 134 (depends on 89)

A method for detecting the presence of Tissue Factor in a sample, comprising:
contacting the sample with the antibody of claim 89 under conditions that allow for formation of a complex between the antibody or bispecific molecules and Tissue Factor; and
analyzing whether a complex has been formed.

### Claim 135 (depends on 89)

A kit for detecting the presence of Tissue Factor in a sample comprising:
the antibody of claim 89; and
instructions for use of the kit.
